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Objective: Cognitive impairment is a common feature of Parkinson disease (PD), for
which age is a major contributing factor. Insulin-like growth factor-1 (IGF-1) declines
with age and contributes to age-related cognitive impairment in PD. Cyclic glycine-
proline (cGP) is a metabolite of IGF-1 and normalizes bioavailable IGF-1. Plasma
cGP/IGF-1molar ratio that represents bioactive IGF-1 in circulation,mayassociatewith
the cognitive status in PD.
Methods:We examined the association of plasma cGP/IGF-1 molar ratio with the cog-
nitive scores or age in PD patients with normal cognition (PD-N, n = 74), mild cogni-
tive impairment (PD-MCI, n = 71), or dementia (PD-D, n = 33), and with the cognitive
scores in 23 age-matchedhealthy controls. Plasma concentrations of IGF-1, IGFbinding
protein-3, and cGP were evaluated using enzyme-linked immunosorbent assay (ELISA)
and high-performance liquid chromatography-mass spectrometry (HPLC-MS), respec-
tively.
Results: The cGP/IGF-1 molar ratio was positively correlated with the age of PD-N
group, negatively correlated with the age of PD-D group, and not associated with the
ageofPD-MCI group. Independent of age, the cGP/IGF-1molar ratiowaspositively cor-
related with the cognitive scores of healthy controls, but not in PD groups.
Conclusion:Oldhealthy peoplewith a higher cGP/IGF-1molar ratio showedbetter pre-
served cognition, possibly due to improved IGF-1 function. Increased cGP/IGF-1 molar
ratio with agemay contribute to cognitive retention in the PD-N group. The absence or
reversal of such association with age in the PD-MCI and PD-D groups may indicate the
conversion of cognitive status in PD, if confirmed through longitudinal investigations
within the individuals with advancing cognitive impairment.
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1 BACKGROUND
Vascular health is critical for maintaining normal cognition in
humans.1,2 Functional plasma insulin-like growth factor-1 (IGF-1)
plays an essential role in vascular remodeling of the adult brain3 and
supports the retention of normal cognition.4 Plasma IGF-1 declines
with age,5 which is amajor contributing factor to cognitive impairment
in old people those are 60 and older.4–7 Given that Parkinson disease
(PD) is an age-related neurological condition, the decline of IGF-1
with age might contribute to cognitive decline in PD.5,8–10 Compared
with the normal aging population, patients with PD have a higher risk
of developing cognitive impairment,11 and those with mild cognitive
impairment (PD-MCI) have a higher risk of developing dementia (PD-
D) than PD patients with normal cognition (PD-N).12,13 Poor cognition
in patients with PD is a recognized primary problem affecting patient
and carer well-being.14,15 A reliable plasma biomarker for predicting
and tracking the changes in cognitive status may assist in identifying
patients at greater risk of developing dementia and the window of
opportunity for suitable intervention.
Plasma concentration of IGF-1 has been under clinical evaluation
as a potential biomarker for IGF-1 function and its association with
cognitive status of PD.8,16 However, the findings have been mixed and
difficult to interpret8,16 because the majority of plasma IGF-1 is not
bioavailable. Themajority of plasma IGF-1 is bound to IGF-binding pro-
teins (IGFBP)-3. This high-affinity binding prevents IGF-1 from activat-
ing its functional receptors.17 Alternatively, the ratio of IGF-1/IGFBP-
3 has been evaluated as a marker of the amount of unbound bioactive
IGF-1.17 Although the IGF-1/IGFBP-3 ratio may help to identify func-
tional plasma IGF-1, its does not have clear association with cognitive
function.18
Our recent clinical and experimental studies suggest that the rel-
ative concentration of cyclic glycine-proline (cGP) to IGF-1 (cGP/IGF-
1 molar ratio) represents the amount of bioavailable IGF-1 in plasma
and has been shown to be a reliable biomarker of functional IGF-1 in
circulation.19–22 As a stable metabolite from a major binding site of
IGF-1,23 cGP retains the binding affinity to IGFBP-3 and effectively
competes with IGF-1 to bind to plasma IGFBP-3, and it does so, in a
concentration-dependent manner.19 A higher concentration of plasma
cGP would occupy a greater proportion of IGFBP-3 and increase the
amount of free, bioavailable IGF-1.19–22 To determine the potential
association between plasma cGP/IGF-1 molar ratio and cognitive sta-
tus, this cross-sectional study examined plasma concentrations of IGF-
1, cGP, and IGFBP-3, and their ratios in PD patients with normal cogni-
tive function, MCI, and dementia.
2 METHODS
2.1 Study population and design
The study was approved by the Southern Health and Disability Ethics
Committee (URB-09-08-037). A convenience sample of patients with
PD (n = 204) was recruited through a movement disorders clinic
RESEARCH INCONTEXT
1. Systematic review: We reviewed (1) insulin-like growth
factor-1 (IGF-1) function in vascular health and its asso-
ciationwith cognitive impairment and age; (2) biomarkers
representing plasma IGF-1 function and their link to cog-
nitive status in Parkinson disease (PD); (3) cyclic glycine-
proline (cGP) function inmemory and its role in regulating
bioavailable IGF-1 inplasma; and (4) theassociationof the
cGP/IGF-1 molar ratio with stroke recovery, obesity, and
hypertension.
2. Interpretation: The changes in the cGP/IGF-1 molar ratio
with agemay assist in predicting cognitive status, and the
risk and conversions of mild cognitive impairment (MCI)
to dementia in PD.
3. Future directions: This article proposes future studies:
(1) confirmation of the age-related changes in cGP/IGF-
1 molar ratio and its association with cognitive status
through longitudinal studies; (2) evaluation of improved
vascular remodelling mediates cGP effect on cognitive
function in a clinical setting; 3) evaluation of improved
cerebral circulation may aid the reduction of the pathol-
ogy of dementia.
(Figure 1). Healthy control participants (n = 24) were recruited from
the local community. Twenty-six PD patients were excluded from
the study due to incomplete cognitive assessments (n = 24) and
the subsequent diagnosis of atypical symptoms (n = 2). One control
participant was excluded due to an MCI classification. Plasma samples
and neurological and cognitive assessments were available for 23
control participants, 74 PD with normal cognitive (PD-N), 71 PD with
mild cognitive impairment (PD-MCI), and 33 PDwith dementia (PD-D,
Figure 1). All participants took their usual medications on the day of
testing to allow for optimal performance. All testing was performed in
themorning.
2.2 Inclusion criteria
Patients with PD included in the study were between age 50 and
90 years of age and meeting UK Brain Bank criteria24 for idiopathic
PD as confirmed by amovement disorders neurologist (T.J.A.). Patients
with cognitive impairment exhibited motor features of PD for at least
12months before the onset of cognitive impairment.
2.3 Exclusion criteria
Participants were excluded if there was a history of central nervous
system (CNS) disorders other than PD (eg, stroke or head injury), any
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other explanation for parkinsonism or cognitive impairment, major
medical illness, major depression in the last 6 months, and other major
psychiatric disorders, dementia with Lewy bodies, and inability to
speak and read English.
2.4 Assessments of cognitive status
Cognitive status was determined using a battery of assessments meet-
ing the requirements of the movement disorder society-task force
(MDS-TF) Level II criteria.24,25 Five cognitive domains were exam-
ined, with the tests conducted over two sessions.26,27 Executive func-
tion was assessed using Stroop interference, letter fluency, cate-
gory fluency, and category switching (from the Delis-Kaplan Exec-
utive Function System 45), action fluency, and Trails B. Attention,
working memory, and processing speed were evaluated using dig-
its forward/backward, digit ordering, map search task (from the Test
of Everyday Attention), Stroop colour reading, Stroop word read-
ing, and Trails A. Memory was measured with the California Ver-
bal Language Test-II Short Form (acquisition, short and long delays),
and the Rey Complex Figure Test (short and long delays); impairment
in either or both delay components of each memory test counted
as one impairment. Visuoperceptual/visuospatial performance was
determined using the judgment of line orientation, fragmented letters
test, the picture completion test, and the Rey Complex Figure Test-
Copy. Language was assessed using the Boston Naming Test, Demen-
tia Rating Scale-2 similarities sub-test, and the language component of
the Alzheimer’s Dementia Assessment Cognitive Scale (object and fin-
ger naming, commands, comprehension, spoken language, and word-
finding difficulties). Scoring of the neuropsychological tests was con-
ducted using age- and education-adjusted normative data. Participants
also completed the Montreal Cognitive Assessment (MoCA). Global
cognitive ability is expressed as an aggregate score (Global Z score)
derived from averaging performance from tests conducted in four cog-
nitive domains.
Classification of PD-MCI required two deficits of 1.5 standard
deviations (SD) or more below age- and education-adjusted norms
within one cognitive domain, but with the maintenance of everyday
functioning.26,27 A PD-D classification required cognitive impairments
of 2 SD below normative data in each of two measures within one or
more cognitive domains as well as impairments in everyday function-
ing not attributed tomotor deficits. Everyday functioningwas assessed
through interviews with a significant other using the Clinical Demen-
tia Rating, theGlobal Deterioration Scale, and the Reisberg Instrumen-
tal Activities of Daily Living-Scale.26–28 The motor function of the PD
patientswas assessed using the part III of theMDS-Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS III) and Hoehn and Yahr staging
(H&Y).
2.5 Plasma sample collection and preparation
Non-fasting venous blood was collected in the morning using lithium
heparin tubes (Becton Dickinson) and gently inverted as per manufac-
ture directions. Filled tubes were placed on wet ice and immediately
transferred to the processing laboratory. The samples were spun in a
cooled centrifuge (4◦C) for 10 minutes at 2000g and plasma stored as
250 µL aliquots at−80 ۤ◦C until assayed.
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2.5.1 Plasma extraction of cGP
Themethodology of extraction of cGP from plasma has been described
previously.20,21 The cGP-1,5,6,7,8-13C, 4-15N (cGP-4x13C, 1 × 15N)
provided an internal standard for the cGP assay. Briefly, cGP-4x13C, 1
× 15N (50 µL of 500 ng/mL)wasmixedwith 100 µL of plasma, and then
transferred to a Phree phospholipid removal cartridge (Phenomenex,
Auckland, New Zealand). Five hundred milliliters of 1% formic acid in
acetonitrile was added to the cartridge and centrifuged at 284g for 5
minutes at 4◦C. The filtrate was dried using a vacuum concentrator.
The dried samples were reconstituted in 100 µL 10% methanol/water
(v/v) and transferred to an ultrapressure liquid chromatography vial
for quantitation, and then centrifuged at 142g for 4 minutes at 4◦C
to sediment any remaining particulates. Standards were prepared by
spiking cGP into charcoal-stripped human plasma. Quality control
samples, with cGP at two different concentrations (Bachem, G-1720),
were utilized and then subjected to the same extraction procedure as
the samples.
2.5.2 High-performance liquid chromatography
mass spectrometry (HPLC-MS)
The chromatography conditions consisted of a Synergy Hydro 2.5 µm
column (Phenomenex) 100 × 2 mm with an initial mobile phase com-
position of 10% methanol/90% water at a flow rate of 200 µL/minute
and a column temperature of 35◦C, as described previously.20,21 The
mass spectrometry conditions consisted of electrospray ionization in
positive mode with a voltage of 4000 V, a sheath gas flow of 30 psi, an
auxiliary gas flow of 2 psi, and a capillary temperature of 250◦C. Frag-
mentation was achieved with argon at 1.2 mTorr as the collision gas
and a dissociation voltage of 35 V. The mass spectrometer ran in selec-
tive reactionmonitoring (SRM)modewith the following two transitions
155.1→ 70.2m/z and 161→ 75.1m/z utilized for cGP and cGP-4x13C,
1 × 15 N, respectively. The retention time for both peaks was 3.6 min-
utes. Unknown samples were quantitated using the peak area ratio of
cGP/cGP-4x13C, 1 × 15N compared with the standard curve of known
concentrations.
2.5.3 Measurement of plasma concentrations of
IGF-1 and IGFBP-3 using ELISA
Plasma concentration of IGF-1 and IGFBP-3 were measured using
commercial enzyme-linked immunosorbent assay (ELISA) kits (Crystal
Chem, Chicago, IL) according to themanufacturer’s instructions.20,21
2.6 Statistical analysis
SPSS (IBM SPSS Statistics 24, Chicago, IL) was used for statistical anal-
ysis. The differences between the control and PD-N groups were ana-
lyzed using t test or Mann-Whitney U test. The differences between
PD groups were analyzed using one-way analysis of variance (ANOVA)
with Tukey post hoc tests or Kruskal-Wallis test with Dunn-Bonferroni
post hoc test. The chi-square test was used to compare gender dif-
ferences. The associations between biological measures and cognitive
scores were analyzed in control and PD groups using multiple linear
regression analysis after being adjusted for motor scores and age. The
association betweenbiologicalmeasureswith agewere analyzed in the
controls and PD groups using multiple linear regression after being
adjusted formotor and/or cognitive scores.As a secondary analysis, the
associationof biologicalmeasureswith agewas comparedbetween the
PD groups using multiple linear regression analysis. The significance
level was set at P < 0.05. Data are presented as mean± standard error
of themean (SEM) unless otherwise stated.
3 RESULTS
Table 1 shows the demographic, clinical, and biological differences
between the control and PD-N groups andwithin the PDgroups. There
was no difference in the age between the controls and combined PD
groups, although the PD-N group was younger than the control (P <
0.05), PD-MCI (P < 0.05), and PD-D (P < 0.05) groups. The function
of cGP in improving learning and memory has been documented
previously in rats.22,29,30 Thus we compared the scores of learning and
memory domain (LMD), MoCA, and Global Z between the control and
PD groups. TheMoCA (P= 0.01), Global Z (P< 0.001), and LMD scores
(P= 0.001)were lower in PD-N compared to controls, and as expected,
these scores were further reduced in PD-MCI (P < 0.05) and PD-D
groups (P< 0.05) compared to PD-N and PD-MCI groups, respectively.
Plasma IGF-1 was significantly lower in the PD-D group compared to
the PD-N and PD-MCI groups (P < 0.05). IGF-1/IGFBP-3 ratio was
higher in the PD-N group than the control group (P < 0.05). Biological
measures remained the samewhen the analysis being adjusted for age.
Table 2 presents the association of biological measures with cogni-
tive scores (MoCA, Global Z, and LMD) in both healthy control and PD
groups after being adjusted for age and/orMDS-UPDRS III scores. The
results showed that the cGP concentration was positively associated
with MoCA (B = 0.1, P = 0.006), Global Z (B = 0.02, P = 0.009), and
LMD scores (B = 0.05, P = 0.01) of the normal control group; as was
cGP/IGF-1 molar ratio (MoCA: B = 0.25, P = 0.016; Global Z: B = 0.07,
P = 0.02; and LMD: B = 0.16, P = 0.01). The IGF-1 and IGFBP-3 con-
centrations were not associated with the cognitive scores of control
group. The analysis did not show any relationship between biological
measures and cognitive scores in PD groups after being adjusted for
age and/or MDS-UPDRS III scores. The data suggest that the healthy
participants with higher plasma cGP and cGP/IGF-1 molar ratio have
better preserved cognitive function. Suchassociationwas absent inPD.
Table 3 shows the association of biological measures with age after
the adjustment for motor (MDS-UPDRS III) and/or cognitive scores
(MoCA,Global Z, and LMD) in the control and PDgroups. The cGP con-
centration (B= 0.39, P= 0.02) and cGP/IGF-1molar ratio (B= 0.96, P=
0.04) were positively associatedwith the age of the control group after
being adjusted for MoCA, but not for Global Z score and LMD scores.
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Age (years) 74.53 (1.37) 70.91 (0.82) 72.89 (0.76) 76.17*,† (0.93) 0.03 0.001
Female/male 8/15 28/46 19/52 5/28 ns 0.049
Education (years) Median (range) 13 (10-18) 13 (9-20) 11*(8-19) 11 (9-20) ns 0.005
Years since symptom duration 11.56 (0.61) 11.60 (0.57) 11.40 (1.19) ns
Years since diagnosis 8.96 (0.53) 10.04 (0.56) 10.07 (1.17) ns
LEDMedian (range) 845.37 (0-3893) 914.38 (0-3162) 798.00 (0-3140) ns
BMI 25.85 (0.89) 26.30 (0.52) 26.35 (0.63) 25.35 (0.50) ns ns
MoCA 27.57 (0.32) 26.51 (0.27) 22.53* (0.34) 16.85*,† (0.86) 0.01 <0.001
Global Z score 0.87 (0.08) 0.33 (0.06) −0.85* (0.06) −1.79*,† (0.14) <0.001 <0.001
LMD score 1.43 (0.19) 0.67 (0.10) −0.72* (0.10) −1.80*,† (0.20) 0.001 <0.001
H&YMedian (range) 2.50 (1-3) 2.50** (1-5) 3.00*** (2-5) <0.001
MDS-UPDRS III 35.20 (1.68) 43.73* (1.84) 48.95* (2.95) <0.001
IGF-1 (ng/mL) 146.27 (10.41) 159.50 (6.03) 160.30 (5.95) 135.20*,† (8.15) ns 0.03
IGFBP-3 (ng/mL) 3332.92 (154.22) 3128.31 (74.55) 3166.86 (85.41) 2865.40 (122.71) ns ns
cGP (ng/mL) 7.44 (1.69) 7.41 (0.54) 7.56 (0.61) 6.24 (0.74) ns Ns
cGP/IGF-1molar ratio 2.32 (0.61) 2.07 (0.17) 2.11 (0.20) 2.10 (0.31) ns Ns
IGF-1/IGFBP-3molar ratio 0.18 (0.009) 0.21 (0.007) 0.21 (0.007) 0.19 (0.008) 0.03 ns
PD-N, Parkinson disease with normal cognitive function; PD-MCI, Parkinson disease with mild cognitive impairment; PD-D, Parkinson disease with demen-
tia; LED, levodopa equivalent dose; BMI, body mass index; H&Y, Hoehn and Yahr score; MDS-UPDRS III, Movement Disorder Society—Unified Parkinson’s
DiseaseRating Scale III;MoCA,Montreal CognitiveAssessment; LMD, LearningMemoryDomain scores; Global Z score, globalmeasure of cognitive function
derived from comprehensive neuropsychological testing.
Parametric datawere analyzed using t test and one-wayANOVAwith Tukey post hoc tests for comparison between controls and PD-N andwithin PD groups,
respectively, and presented as mean (SEM). Non-parametric data were analyzed using Mann-Whitney U test and Kruskal-Wallis test with Dunn-Bonferroni
post hoc test accordingly and presented asmedian (range). The gender effects were analyzed using chi-square test.
*P< 0.05, **P< 0.01, ***P< 0.001 indicating the differences from PD-N group;
†P< 0.05, ††P< 0.01 indicating the difference from PD-MCI.
Plasma IGF-1 and IGFBP-3 concentrations were not associated with
the age of control group after being adjusted for the cognitive scores.
IGF-1 concentration was negatively associated with the age of the
PD-N group after being adjusted for MDS-UPDRS III and MoCA (B =
−0.03, P = 0.02) or Global Z (B = −0.03, P = 0.01) or LMD (B = −0.03,
P= 0.02) scores, respectively. cGP concentrationwas positively associ-
ated with the age of PD-N group after being adjusted forMDS-UPDRS
III and Global Z (B= 0.36, P= 0.05) or LMD (B= 0.37, P= 0.04) scores,
respectively. cGP/IGF-1 molar ratio was positively associated with
the age of PD-N group after being adjusted for MDS-UPDRS III and
MoCA (B = 1.57, P = 0.004) or Global Z (B = 1.77, P = 0.002) or LMD
(B = 1.84, P = 0.001) scores, respectively. There was no association
between the biological measures and the age in the PD-MCI group
after being adjusted for motor and cognitive scores. In contrast, cGP
(B = −0.70, P = 0.04) and cGP/IGF-1 molar ratio (B = -3.56, P = 0.003)
was negatively associated with the age of PD-D group after being
adjusted for MDS-UPDRS III and MoCA scores. There were no Global
Z and LMD data in PD-D group. The data suggested that the changes
of cGP/IGF-1 molar ratio with age were different between PD-N and
PDwith cognitive impairments.
The comparison between the PD groups with normal and impaired
cognitive status showed that the age of the PD-N group was positively
associated with cGP concentration (B = 0.16, P = 0.04, Figure 2D)
and cGP/IGF-1 molar ratio (B = 0.09, P < 0.001, Figure 2G), whereas
negatively associated with IGF-1 concentration (B = −2.85, P < 0.001,
Figure 2A) and IGF-1/IGFBP-3 molar ratio (B = −0.003, P < 0.01,
Figure 2M). The age of PD-MCI (Figure 2B, E, H, K, and N) and PD-D
groups (Figure 2 C, F, I, L, and O) was not associated with the biological
measures. Compared to the PD-N, the association slope of cGP/IGF-1
molar ratio was reversed in the PD-D group (B = −0.18, P < 0.001,
Table 4), but not in PD-MCI group. The data further support that the
age effects on the biological measures were differently associated
with the cognitive status of PD and that the cGP/IGF-1 molar ratio
increases with age in PD-N, whereas it decreases in PD-D.
4 DISCUSSIONS
Our findings suggest that old healthy people with a higher cGP/IGF-1
molar ratio have better preserved cognition independent of age, possi-
bly due tomore bioavailable IGF-1 in circulation. The cGP/IGF-1molar
ratio increased with age in the PD-N. However, such an association
with age was absent in the PD-MCI and reversed to a decrease in
the cGP/IGF-1 molar ratio with age in the PD-D. These age-related
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Control MoCA (Age) n= 23 B 0.005 0.10 0.25 0.001 12.09
P 0.42 0.006** 0.01* 0.35 0.07
Global Z score (Age) n= 23 B 0.000 0.02 0.07 0.000 1.86
P 0.99 0.009** 0.02* 0.27 0.35
LMD (Age) n= 23 B −0.002 0.05 0.16 0.000 3.04
P 0.59 0.01* 0.01* 0.08 0.47
PD-N MoCA (Age andMDS-UPDRS III) n= 70 B −0.007 −0.04 −0.16 0.001 −8.57
P 0.24 0.52 0.44 0.22 0.07
Global Z score (Age andMDS-UPDRS III) n= 67 B −0.001 −0.01 −0.03 0.00 0.02
P 0.70 0.32 0.46 0.70 0.98
LMD (Age andMDS-UPDRS III) n= 67 B 0.00 −0.02 −0.11 0.00 1.55
P 0.65 0.35 0.18 0.52 0.43
PD-MCI MoCA (Age andMDS-UPDRS III) n= 63 B 0.00 −0.11 −0.23 0.00 −3.30
P 0.99 0.14 0.40 0.78 0.63
Global Z score (Age andMDS-UPDRS III) n= 61 B 0.00 −0.003 −0.001 0.00 0.01
P 0.71 0.82 0.98 0.36 0.99
LMD (Age andMDS-UPDRS III) n= 61 B 0.00 0.02 0.05 0.00 1.71
P 0.81 0.29 0.36 0.33 0.38
PD-D MoCA (Age andMDS-UPDRS III) n= 22 B 0.008 0.44 0.12 0.001 −0.09
P 0.71 0.15 0.59 0.29 0.63
PD-N, Parkinson diseasewith normal cognitive function; PD-MCI, Parkinson diseasewithmild cognitive impairment; PD-D, Parkinson diseasewith dementia;
MDS-UPDRS III, Movement Disorder Society—Unified Parkinson’s Disease Rating Scale III; MoCA,Montreal Cognitive Assessment; LMD, LearningMemory
Domain scores;Global Z score, globalmeasureof cognitive functionderived fromcomprehensiveneuropsychological testing; B, unstandardized co-efficiency.
*P< 0.05.
**P< 0.01.
variations in cGP/IGF-1 molar ratio may assist in identifying cognitive
status and the risk of advancing cognitive impairment in PD. This inter-
pretation, if further confirmedby longitudinal studies, has thepotential
to be developed for clinical use as a prognostic biomarker for cognitive
status of PD.
The changes of circulating IGF-1 and IGFBP-3 have been under
clinical evaluations for their potential association with PD and their
cognitive status with inclusive and inconsistent outcomes.8,16,31,32 It
is known that plasma IGF-1 concentration decreases with age,5,18
whereas it increases in PD.31,32 As a neurodegenerative condition, PD
may confound the age effect on plasma concentration of IGF-1, and the
subsequent changes in plasma cGP and IGFBP-3. The collective effects
of aging and PD led to a moderate decrease in IGF-1 concentration
of the PD-D group, with cGP and IGFBP-3 concentrations remaining
similar between the groups. Multiple linear regression analysis after
the adjustment for confounding factors revealed that these biological
measures were associated with normal cognitive function in healthy
controls independent of age (Table 2), whereas they were associated
with age in the PDgroups independent of cognitive andmotor function
(Table 3).
Better preserved cognitive function of old healthy people was asso-
ciated with higher plasma concentration of cGP and/or cGP/IGF-1
molar ratio, which was independent of age. The data support a role for
cGP inmaintaining cognitive function during brain aging. The effects of
cGP inmemory have been reported previously in rats.22,29,30 For exam-
ple, maternal administration of cGP improves learning and memory in
young male rats.22 The plasma concentration of IGF-1 and molar ratio
of IGF-1/IGFBP-3 have been under clinical evaluation for predicting
the cognitive function of old people with inconsistent outcomes.4,6,7,18
Our data did not suggest the relationship between cognitive scores
and IGF-1 concentration and IGF-1/IGFBP-3 molar ratio in normal
controls (Table 3). Thus cGP concentration and cGP/IGF-1 molar ratio
may be more closely related to the cognitive function of healthy old
people.
Such an association with cognitive function was absent in PD
groups, possibly due to their lower cognitive scores and abnormal cog-
nitive function. Although the cognitive function of PD-Nwas “normal,”
the group had significant lower scores when compared to the healthy
control group. This may suggest an initial decline of cognition in the
PD-N due to accelerated brain aging in PD. Age-related decline of IGF-
1 is a major contributor to cognitive impairment, including in PD.4–8,16
Our results suggest that the biological measures of PD groups changed
with age,whichwere dependent on the cognitive status (Tables 3 and4,
Figure 2).
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Control Age (MoCA) n= 23 B −0.01 0.39 0.96 −0.003 22.83
P 0.53 0.02* 0.04* 0.12 0.46
Age (Global Z score) n= 23 B −0.02 0.16 0.38 −0.002 −4.61
P 0.35 0.43 0.50 0.27 0.88
Age (LMD) n= 23 B −0.02 0.12 0.27 −0.002 −4.49
P 0.42 0.54 0.63 0.37 0.88
PD-N Age (MoCA&MDS-UPDRS III) n= 70 B −0.03 0.29 1.57 −0.001 −26.47
P 0.01* 0.09 0.004** 0.55 0.052
Age (Global Z score &MDS-UPDRS III) n= 67 B −0.03 0.36 1.77 −0.002 −19.57
P 0.02* 0.05 0.002** 0.25 0.17
Age (LMD&MDS-UPDRS III) n= 67 B −0.03 0.37 1.84 −0.002 −21.00
P 0.02* 0.04* 0.001** 0.21 0.13
PD-MCI Age (MoCA&MDS-UPDRS III) n= 63 B −0.02 0.28 1.13 −0.001 −15.85
P 0.17 0.12 0.06 0.36 0.32
Age (Global Z score &MDS-UPDRS III) n= 61 B −0.02 0.21 0.56 −0.001 −11.79
P 0.24 0.20 0.26 0.40 0.45
Age (LMD&MDS-UPDRS III) n= 61 B −0.02 0.18 0.50 −0.001 −13.94
P 0.21 0.26 0.32 0.40 0.37
PD-D Age (MoCA&MDS-UPDRS III) n= 22 B 0.003 −0.70 −3.56 0.001 −1.64
P 0.90 0.04* 0.003** 0.65 0.95
PD-N, Parkinson diseasewith normal cognitive function; PD-MCI, Parkinson diseasewithmild cognitive impairment; PD-D, Parkinson diseasewith dementia;
MDS-UPDRS III, Movement Disorder Society—Unified Parkinson’s Disease Rating Scale III; MoCA, Montreal Cognitive Assessment; LMD, learning memory
domain scores; Global Z score, globalmeasure of cognitive function derived fromcomprehensive neuropsychological testing; B, unstandardized co-efficiency.
*P< 0.05; **P< 0.01 indicate significant correlation of age and biological measures.
Plasma IGF-1 decreased with age of the PD-N group. As an
autocrine response to improve the amount of bioavailable IGF-1 in
plasma,19–22 cGP correspondingly increased with age, leading to an
age-associated increase of cGP/IGF-1 molar ratio in the PD-N group
(Table 3 and Figure 2G). The increase of the cGP/IGF-1molar ratiowith
age is a compensatory response to the age-related decline of IGF-1
function in circulation that may contribute to the preserved cognitive
function in PD-N patients.
This age-related increase in cGP/IGF-1 ratio in the PD-N group
was absent in the PD-MCI group (Table 3, Figure 2H), whereas it was
statistically reversed to a decrease with age in the PD-D group (ie,
lower ratio with greater age). This negative association was driven
clearly by a progressive decline of cGP with age (Tables 3 and 4, Fig-
ure 2F). Low plasma concentration of cGP and/or the cGP/IGF-1 molar
ratio has been suggested to be associated with impairment of the
autocrine regulation of IGF-1 in hypertension21 and stroke patients,20
and may also contribute to cognitive impairment in PD. Indeed, the
administration of cGP can prevent ischemic brain injury,19,33 normal-
ize blood pressures,34 and improve memory in rats.22 A longitudinal
study shows that the cGP/IGF-1 molar ratio increases while patients
recover from stroke and that the cGP/IGF-1 molar ratio at hospital
admission (<3 days of stroke) predicts 3 months recovery and clinical
outcome of stroke.20 These age-related observations in PD need to
be validated through longitudinal studies in individuals with advanc-
ing cognitive impairments. If confirmed, the changes of cGP/IGF-1
molar ratio with age may potentially be used as a biomarker for assist-
ing the diagnosis and/or prognosis of cognitive risk and conversions
of PD.
Poor vascular health, like hypertension, is a common risk factor con-
tributing to cognitive impairment in PD and stroke patients.35–37 The
function of plasma IGF-1 is essential for cerebral vascular remodeling
of mature brains and is mediated through the blood face of cerebral
vessels.3 The administration of cGP protects neuronal and, more so,
vascular injury from ischemia through promoting IGF-1-mediated vas-
cular protection/remodeling in rats.19 Given the nature of cerebral vas-
cular degeneration/dysfunction in age-related cognitive impairment,38
the changes in the plasma cGP/IGF-1 molar ratio may represent IGF-
1-mediated cerebral vascular function/remodeling and its association
with cognitive function. Given the role of cGP in memory,22 we specu-
late that intervention with cGPmay restore the cGP/IGF-1 molar ratio
and improve the cognitive function in PD patients with progressive
decline of plasma cGP and/or cGP/IGF-1molar ratio.
The small number of control participants and PD-D patients used
for analysis is a limitation of the study. However, the publication of this
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F IGURE 2 Compares the age effects on the concentrations of IGF-1 (A-C), cGP (D-F), and IGFBP-3 (J-L); and cGP/IGF-1molar ratio (G-I) and
IGF-1/IGFBP-3molar ratio (M-O) between the PD-N, PD-MCI, and PD-D groups. The IGF-1 concentration and IGF-1/IGFBP-3molar ratio were
negatively associated with age, whereas the cGP concentration and cGP/IGF-1molar ratio were positively associated with age in the PD-N group.
Compared to the changes in the PD-N group, the biological measures were differently associated with age in the PD-MCI and PD-D groups, with
strong interactions between the PD groups
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TABLE 4 Changes of association slope between biological

























PD-N, Parkinson’s disease with normal cognitive function; PD-MCI, Parkin-
son’s disease with mild cognitive impairment; PD-D, Parkinson’s disease
with dementia; B, unstandardized co-efficiency, PD-N: n = 74; PD-MCI:
n= 71; and PD-D: n= 33.
hypothesis-generating findingwill promote research for confirming the
hypothesis through larger and longitudinal studies.
5 CONCLUSION
An increase in plasma cGP/IGF-1 molar ratio with age may contribute
to the preserved cognitive function in the PD-N group. In contrast,
the decrease in the ratio with age may be associated with dementia
in the PD-D group. The static relationship between cGP/IGF-1 molar
ratio and age in the PD-MCI group could be a transition phase before
dementia. These observations raise the possibility that the association
between cGP/IGF-1 ratio and age may assist prediction of cognitive
status and risk of advancing cognitive impairment in patients with PD
if further confirmed in longitudinal research.
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